Member Info for inanaco

Chester

well the Clock is ticking ........ March 29th ... its Freedom Day ..at 11pm

Tick Tock

with Scancell its been like a stop watch ! ... however it would appear that the market is winding up the clock again ..

so a tick tock "should be heard" .. said Bercow

Can you confirm that you are not the mathematician Diane Abbott ....

Pfizer (US) 51.6 22.0

so how did you get to 23% ... on those numbers

Oh Clever one ...

the list i presented earlier is the list you worked from

as every qtr yields a different number .... what is clear it not representative of the single figure 5% you implied for Bio Tech Profits relative to turnover ..

the question then should be ... from the list i quoted ... how did you get to 23%

and really what prompted you to consider 5% ... ?

I would also point out a tax credit also sits in a profit and loss account ...

yours ? is it one block of 200,000

Factual postings ... LOL

unlike Ruck with his 23% ... or indeed 5% implied ..

led by clinical-phase NY-ESO-1 asset SCIB1 ...........

that should read Tpr2/gp100 asset SCIB1

its only petrol money ...

i just did a quick search on % ... which delivered those numbers as a combined link .... from various Pharma

Pfizer

Dec. 31, 2012 45.46%

its current is

Sept. 30, 2018 30.94%

those numbers are $ ... not %

so $51 Billion turnover yields $22 billion profit ...

how does that become 23% ?

then how does pfizer make a staggering 43% ....

Product my boy all down to Product ....

you don't understand the market profit percentages ... after all you re the lowest at 5%

scancell has already advised it will not run Phase 3 .. and will be a Royalty based company ..

Costs to date are reflected in Balance sheet ...

again your entire argument today is based on "Not What Scancell is doing" but on what Big Pharma are doing

sorry if you have stage 4 and failed treatment ... no commercial product exists ... so no market exists ..

welcome to Moditope ....... hences its created its own market ...

Moditope creates a market for itself ......................... it does not take market share ...

and if the standard of care provided by PD1 in late stage ... is surpassed ... it takes that as well ...

that is why you get End Points in trials .... efficacy v Standard of care ....

PD1 has become a dominant player ...and is capturing "market share" 30% of patient efficacy at best

Patients taking Moditope ... have no other choice if the fail PD1's or it never worked, even with vaccine the numbers rise to at best 55%

so its potentially 100% of the market at that point ... as nothing else exists

You are not even in tune with Pharma Average ... this is the problem when you make wild statements without any research and blag your way through posting on here trying to justify ..

what for ?

5% into context

World's largest pharmaceutical firms
Company Total revenue ($bn) Profit ($bn)
Johnson & Johnson (US) 71.3 1 3.8
Novartis (Swiss) 58.8 9.2
Pfizer (US) 51.6 22.0

i just advised the market size ... Ruck

Its you that tried to put % and numbers to it .........

My £8 is based only on phase 2 numbers ... with deals signed ... wait and see eh !

over the life of the patent they get written back

never seen a trial cost. eat up 95% of the sales price ... what lunatic would make that investment ... make more profit on a bag of crisps as a % profit margin

you are severely lacking in any commercial Nous ..

is a MAB ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759494/

Ruck ... work it out ...

are you telling me that a $150,000 PD-1 treatment cost ... 5% profit .... so $142,500 to manufacture and sell . ? Cough

look a flue vaccine is available at £15 ... from Boots

Funny thing is its a peptide with an adjuvant

scancell moditope is a bit more refined technically to build ... but the ingredients are the same ...